Schering-Plough PEG-Intron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Peginterferon alfa-2b is approved Jan. 19 for once-weekly monotherapy to treat chronic hepatitis C in patients not previously treated with alpha interferon who have compensated liver disease and are at least 18 years old. PEG-Intron, the first pegylated interferon approved in the U.S., should be available in early February. As a Phase IV commitment, Schering will study whether PEG-Intron produces lower response rates in African-Americans. The company plans to file an application for combination use with Rebetol (ribavirin) in the first quarte